Journal of Nanomaterials / 2019 / Article / Fig 6

Research Article

Doxorubicin and ABT-199 Coencapsulated Nanocarriers for Targeted Delivery and Synergistic Treatment against Hepatocellular Carcinoma

Figure 6

In vivo tumor inhibition of DDS NPs. (a) Volume curves of tumors in each treatment groups. (b) The body weight curves of mice in each group. (c) The tumors in different groups were taken out after euthanasia. Nude mice were transplanted tumors on the left flank. The treatment dosages of ABT-199 and DOX were 10 mg/kg and 1 mg/kg, respectively. Each treatment was intravenously injected two times per week for three weeks. The tumorous volumes and body weights were recorded on the next day after injection. Each group has 6 mice, and error bars represent SD; and .

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.